Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Updated Canadian guideline aims to raise awareness of new HIV prevention strategies

1

Dec 2025

Updated Canadian guideline aims to raise awareness of new HIV prevention strategies

Multiple pre-exposure (PrEP) and postexposure (PEP) treatments are now available to prevent HIV infection. An updated Canadian guideline published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250511 contains 31 recommendations and 10 good practice statements to help clinicians and other health care professionals offer these safe and effective options to teen and adult patients.

Designing better RNA delivery polymers with computational tools

1

Dec 2025

Designing better RNA delivery polymers with computational tools

A research team led by professor Olivia Merkel, Chair of Drug Delivery at LMU and co-spokesperson of the Cluster for Nucleic Acid Therapeutics Munich (CNATM) has developed the first integrated platform that combines molecular dynamics (MD) simulations and machine learning (ML) to identify new polymeric materials for therapeutic RNA delivery.

Study highlights a rising incidence of breast cancers in younger women

1

Dec 2025

Study highlights a rising incidence of breast cancers in younger women

A study of data from seven outpatient facilities in the New York region found that 20-24% of all the breast cancers diagnosed during an 11-year period were found in women age 18 to 49, according to research being presented today at the annual meeting of the Radiological Society of North America (RSNA).

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.